Tech Company Financing Transactions

Editas Medicine Funding Round

On 11/26/2013, Editas Medicine raised $43 million in Series A investment from Flagship Pioneering, Partners Innovation Fund and Polaris Partners.

Transaction Overview

Company Name
Editas Medicine
Announced On
11/26/2013
Transaction Type
Venture Equity
Amount
$43,000,000
Round
Series A
Investors

Flagship Pioneering (Douglas Cole)

Partners Innovation Fund

Polaris Partners (Terry McGuire)

Third Rock Ventures (Alexis Borisy)

Proceeds Purpose
The cash will be used to get the platform ready for prime time, and build out its scientific and operational team so Editas' technology will be ready to go when the company has a better sense of what its priorities will be in clinical trials.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11 Hurley St.
Cambridge, MA 02141
USA
Phone
(617) 401-9000
Website
www.editasmedicine.com
Email Address
[email protected]
Overview
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Profile
Editas Medicine LinkedIn Company Profile
Social Media
Editas Medicine Company Twitter Account
Company News
Editas Medicine News
Facebook
Editas Medicine on Facebook
YouTube
Editas Medicine on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Cynthia Collins
  Cynthia Collins LinkedIn Profile  Cynthia Collins Twitter Account  Cynthia Collins News  Cynthia Collins on Facebook
Chief Medical Officer
Judith Abrams
  Judith Abrams LinkedIn Profile  Judith Abrams Twitter Account  Judith Abrams News  Judith Abrams on Facebook
Chief Scientific Officer
Charles Albright
  Charles Albright LinkedIn Profile  Charles Albright Twitter Account  Charles Albright News  Charles Albright on Facebook
VP - Operations
Harry Gill
  Harry Gill LinkedIn Profile  Harry Gill Twitter Account  Harry Gill News  Harry Gill on Facebook
VP - Regulatory Affairs
Timothy Hunt
  Timothy Hunt LinkedIn Profile  Timothy Hunt Twitter Account  Timothy Hunt News  Timothy Hunt on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/26/2013: Cerevast Therapeutics venture capital transaction
Next: 11/26/2013: Aphios venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.